Invention Grant
US09226930B2 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
有权
1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗神经和精神疾病的用途
![1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders](/docs/US/2016-01-05/US09226930B2/abs.jpg.600x600.jpg)
- Patent Title: 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
- Patent Title (中): 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗神经和精神疾病的用途
-
Application No.: US14556563Application Date: 2014-12-01
-
Publication No.: US09226930B2Publication Date: 2016-01-05
- Inventor: Jose Maria Cid-Nunez , Daniel Oehlrich , Andres Avelino Trabanco-Suarez , Gary John Tresadern , Juan Antonio Vega Ramiro , Gregor James MacDonald
- Applicant: JANSSEN PHARMACEUTICALS, INC. , ADDEX PHARMA S.A.
- Applicant Address: US NJ Titusville CH Geneva
- Assignee: Janssen Pharmaceuticals, Inc.,Addex Pharma, SA
- Current Assignee: Janssen Pharmaceuticals, Inc.,Addex Pharma, SA
- Current Assignee Address: US NJ Titusville CH Geneva
- Agency: Baker & Hostetler LLP
- Priority: EP09160059 20090512
- Main IPC: A61K31/5375
- IPC: A61K31/5375 ; A61K31/5377 ; A61K31/437 ; A61K31/496 ; C07D401/14 ; C07D471/04 ; C07D519/00 ; A61K45/06 ; A61K31/4545 ; A61K9/00 ; A61K9/06 ; A61K9/10 ; A61K9/20 ; A61K31/438 ; A61K31/506
![1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders](/abs-image/US/2016/01/05/US09226930B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
Public/Granted literature
Information query
